<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03549000</url>
  </required_header>
  <id_info>
    <org_study_id>CNZV930X2101</org_study_id>
    <secondary_id>2018-000153-51</secondary_id>
    <nct_id>NCT03549000</nct_id>
  </id_info>
  <brief_title>A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.</brief_title>
  <official_title>A Phase I/Ib, Open-label, Multi-center, Study of NZV930 as a Single Agent and in Combination With PDR001 and/or NIR178 in Patients With Advanced Malignancies.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety, tolerability, and preliminary anti-tumor&#xD;
      activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178,&#xD;
      in patients with advanced cancers&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Anticipated">February 14, 2022</completion_date>
  <primary_completion_date type="Anticipated">January 24, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with adverse events as a measure of safety and tolerability of the NZV930 in combination with PDR001 and/or NIR178</measure>
    <time_frame>3 years</time_frame>
    <description>Incidence and severity of AEs and SAEs, incl. changes in laboratory parameters, vital signs, and ECGs Dose limiting toxicity in cycle 1 (28 days) for single agent NZV930 and NZV930 in combination with PDR001 and/or NIR178 during dose escalation phase only Tolerability: dose interruptions Tolerability: dose reductions Tolerability: dose intensity</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the proportion of patients with best overall response of CR or PR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Benefit Rate (CBR)</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the proportion of patients with best overall response of CR, PR or SD &gt;= 16 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Defined as the time from the date of start of treatment to the date of the event defined as first documented progression or death due to any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum concentration vs. time profiles of NZV930 (free drug) and PDR001.</measure>
    <time_frame>3 years</time_frame>
    <description>Serum concentration vs. time profiles of NZV930 (free drug) and PDR001.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Plasma concentration vs. time profiles for NIR178 and derived PK parameters</measure>
    <time_frame>3 years</time_frame>
    <description>Concentration time profile of NIR178 and its metabolites</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To assess the immunogenicity of NZV930 and PDR001</measure>
    <time_frame>3 years</time_frame>
    <description>Presence and titer of anti-drug antibodies, anti-NZV930 and anti-PDR001 in (patients receiving combination with PDR001).</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">344</enrollment>
  <condition>Non-small Cell Lung Cancer (NSCLC)</condition>
  <condition>Triple Negative Breast Cancer (TNBC)</condition>
  <condition>Pancreatic Ductal Adenocarcinoma (PDAC)</condition>
  <condition>Colorectal Cancer Microsatellite Stable (MSS)</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Renal Cell Carcinoma (RCC)</condition>
  <condition>Metastatic Castration Resistant Prostate Cancer (mCRPC)</condition>
  <arm_group>
    <arm_group_label>NZV930 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single Agent NZV930</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NZV930 with PDR001 Doublet Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of NZV930 with PDR001</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NZV930 with NIR178 Doublet Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of NZV930 with NIR178</description>
  </arm_group>
  <arm_group>
    <arm_group_label>NZV930 with NIR178 &amp; PDR001 Triplet Therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Combination of NZV930 with NIR178 and PDR001</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>NZV930</intervention_name>
    <description>NZV930, Specified dose on specified days, intravenous (IV)</description>
    <arm_group_label>NZV930 Monotherapy</arm_group_label>
    <arm_group_label>NZV930 with NIR178 &amp; PDR001 Triplet Therapy</arm_group_label>
    <arm_group_label>NZV930 with NIR178 Doublet Therapy</arm_group_label>
    <arm_group_label>NZV930 with PDR001 Doublet Therapy</arm_group_label>
    <other_name>Biological</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PDR001</intervention_name>
    <description>PDR001, Specified dose on specified days, intravenous (IV)</description>
    <arm_group_label>NZV930 with NIR178 &amp; PDR001 Triplet Therapy</arm_group_label>
    <arm_group_label>NZV930 with PDR001 Doublet Therapy</arm_group_label>
    <other_name>Biological</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NIR178</intervention_name>
    <description>NIR178 Specified dose on specified days, Orally</description>
    <arm_group_label>NZV930 with NIR178 &amp; PDR001 Triplet Therapy</arm_group_label>
    <arm_group_label>NZV930 with NIR178 Doublet Therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Adult men &amp; women ≥ 18 years of age Histologically confirmed advanced malignancies with&#xD;
        documented progression following standard therapy, or for whom, in the opinion of the&#xD;
        investigator, no appropriate standard therapy exists.&#xD;
&#xD;
        Must have a site of disease amenable to biopsy and be a candidate for tumor biopsy&#xD;
        according to the treating institution's guidelines. The patient must be willing to undergo&#xD;
        a new tumor biopsy at screening and during treatment.&#xD;
&#xD;
        ECOG performance status 0-2 and in the opinion of the investigator, likely to complete at&#xD;
        least 56 days of treatment.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Symptomatic or uncontrolled Brain metastases requiring concurrent treatment, inclusive of&#xD;
        but not limited to surgery, radiation and/or corticosteroids.&#xD;
&#xD;
        Patients with treated symptomatic brain metastases should be neurologically stable for 4&#xD;
        weeks post-treatment prior to study entry and at doses of &lt;10 mg per day prednisolone or&#xD;
        equivalent for at least 2 weeks before administration of any study treatment.&#xD;
&#xD;
        Patients who required discontinuation of treatment due to treatment-related toxicities with&#xD;
        prior immunotherapy.&#xD;
&#xD;
        Patients previously treated with anti-CD73 treatment and/or adenosine receptor A2a (A2aR)&#xD;
        inhibitors.&#xD;
&#xD;
        Active, previously documented, or suspected autoimmune disease within the past 2 years.&#xD;
&#xD;
        Patients with vitiligo, type I diabetes, residual hypothyroidism only requiring hormone&#xD;
        replacement, psoriasis not requiring systemic treatment or conditions not expected to recur&#xD;
        should not be excluded. Additionally, patients previously exposed to anti-PD-1/PD-L1&#xD;
        treatment who are adequately treated for skin rash or with replacement therapy for&#xD;
        endocrinopathies should not be excluded.&#xD;
&#xD;
        History of or current drug-induced interstitial lung disease or pneumonitis grade ≥ 2.&#xD;
&#xD;
        Impaired cardiovascular function or clinically significant cardiovascular disease,&#xD;
        including any of the following: Clinically significant and/or uncontrolled heart disease&#xD;
        such as congestive heart failure requiring treatment (NYHA Grade ≥ 2), uncontrolled&#xD;
        hypertension or clinically significant arrhythmia Patients with corrected QT using the&#xD;
        Fridericia's correction (QTcF) &gt; 470 msec for females or &gt;450 msec for males, on screening&#xD;
        ECG or congenital long QT syndrome Acute myocardial infarction or unstable angina &lt; 3&#xD;
        months prior to study entry History of stroke or transient ischemic event requiring medical&#xD;
        therapy Symptomatic claudication Infection: HIV infection, Active HBV or HCV infection (per&#xD;
        institutional guidelines). Patients with chronic HBV or HCV disease that is controlled&#xD;
        under antiviral therapy are allowed in the expansion but not in the escalation, Known&#xD;
        history of tuberculosis Infection requiring systemic antibiotic therapy. Patients requiring&#xD;
        systemic antibiotics for infection must have completed treatment before screening is&#xD;
        initiated.&#xD;
&#xD;
        Systemic anti-cancer therapy within 2 weeks of the first dose of study treatment. For&#xD;
        cytotoxic agents that have major delayed toxicity, e.g. mitomycin C and nitrosoureas, 6&#xD;
        weeks is indicated as washout period. For patients receiving anticancer immunotherapies, 4&#xD;
        weeks is indicated as the washout period.&#xD;
&#xD;
        Systemic chronic steroid therapy (≥ 10 mg/day prednisone or equivalent) or any&#xD;
        immunosuppressive therapy, other than replacement dose steroids in the setting of adrenal&#xD;
        insufficiency, within 7 days of the first dose of study treatment. Topical, inhaled, nasal,&#xD;
        and ophthalmic steroids are allowed&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>H Lee Moffitt Cancer Center and Research Institute Inc</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Noemi Rodriguez</last_name>
      <phone>813-745-2556</phone>
      <email>noemi.rodriguezGuadalupe@moffitt.org</email>
    </contact>
    <investigator>
      <last_name>Alberto Chiappori</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Texas MD Anderson Cancer Center MD Anderson PSC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yulong Liang</last_name>
      <phone>713-792-7634</phone>
      <email>YLiang7@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Siqing Fu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1Z6</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2W 1T8</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Chuo ku</city>
        <state>Tokyo</state>
        <zip>104 0045</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sutton</city>
        <state>Surrey</state>
        <zip>SM2 5PT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>Japan</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>May 25, 2018</study_first_submitted>
  <study_first_submitted_qc>May 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 7, 2018</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 27, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NZV930</keyword>
  <keyword>PDR001</keyword>
  <keyword>NIR178</keyword>
  <keyword>Immune checkpoint inhibitor</keyword>
  <keyword>immunotherapy</keyword>
  <keyword>CD73</keyword>
  <keyword>PD-1</keyword>
  <keyword>PD-L1</keyword>
  <keyword>A2aR</keyword>
  <keyword>Adenosine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Spartalizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

